Müller W, Stratz T
Hochrhein-Institut, Rheumaklinik, Bad Säckingen, Germany.
Scand J Rheumatol Suppl. 2000;113:59-62. doi: 10.1080/030097400446661.
The observed effects on the symptoms of fibromyalgia of daily oral administration of 5 mg of the 5-HT3 receptor antagonist, tropisetron, for 10 days, could be maintained or exceeded with intravenous administration of only 2 mg of the formulation. Following a single i.v. injection of 2 mg tropisetron, a more rapid and profound reduction in pain was achieved than with 5 mg oral tropisetron per day. In individual cases, patients who had previously experienced no reduction in pain from 10 days of 5 mg oral tropisetron daily responded to i.v. therapy. A more favourable and persistent effect on pain, combined with a simultaneous significant improvement in various vegetative and functional symptoms was achieved with five days treatment with 2 mg tropisetron i.v. per day. The results outlined and the possibility for rapid improvements with drug treatment of fibromyalgia should be confirmed in randomised, placebo controlled trials.
每日口服5毫克5 - HT3受体拮抗剂托烷司琼，持续10天，观察到其对纤维肌痛症状有一定效果；而仅静脉注射2毫克该制剂，就能维持或超过口服给药的效果。单次静脉注射2毫克托烷司琼后，与每日口服5毫克托烷司琼相比，疼痛减轻得更快且更显著。个别情况下，之前每日口服5毫克托烷司琼10天疼痛未减轻的患者，对静脉治疗有反应。每日静脉注射2毫克托烷司琼，治疗五天后，对疼痛产生了更有利且持久的效果，同时各种自主神经和功能症状也有显著改善。概述的这些结果以及通过药物治疗纤维肌痛实现快速改善的可能性，应在随机、安慰剂对照试验中得到证实。
